While other tumor types have seen extraordinary progress with immunotherapy agents such as Opdivo (nivolumab) and Yervoy (ipilimumab), they have not yet shown similar success in the treatment of prostate cancer. Padmanee Sharma, M.D., Ph.D., weighs in.
The American Society for Clinical Oncology (ASCO) recently published a set of recommendations to better care for patients who are sexual and gender minorities.
Efforts to boost Ed's immune system begin to work.
Appointment time, arriving early, and six other easy things you can do to optimize your time with the oncologist
A two-time cancer survivor, breast cancer and melanoma, discusses the empty nest process and cancer.
Laura Yeager, breast cancer survivor, reflects on her journey and life as a survivor in her prose poem “On Losing My Nipples.”
In an interview with CURE, Evan Y. Yu, M.D., discusses the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space and the possibilities for the future treatment landscape.
In an interview with CURE at the Interdisciplinary Prostate Cancer Congress, Celesita Higano, M.D., discussed the early use of chemotherapy, the potential for PARP inhibitors and the evolving role of radium-223 in prostate cancer.
In an interview with CURE, Leena Gandhi, M.D., Ph.D., discussed emerging developments in the first-line treatment for patients with ALK-positive NSCLC, as well as novel agents emerging in the field.
How food can trigger memories and emotions.
A non-runner explains why running and cancer are the same thing. Except they're not.
To assist surgeons in assessing margins in the operating room, The MarginProbe System was created by Dune Medical Devices. Using the tool, surgeons can get immediate information about the presence of cancer cells on the margins of a tumor.
Jessica Yasmine Islam, M.P.H., discusses the changing statistics behind people with HIV and cancer.
Can President Donald Trump be more successful in lowering drug prices than he was in repealing and replacing the Affordable Care Act?
Tecentriq showed impressive long-term survival in patients with metastatic TNBC, according to the results from a recent study.
Does excess weight pose a cancer related health risk for women? Read more to find out.
Cancer often lasts far longer than from diagnosis to remission.
The BTK inhibitor Imbruvica (ibrutinib) was granted a supplemental new drug application (sNDA) by the Food and Drug Administration for the treatment of patients with chronic graft-versus-host-disease (cGVHD).
PARP inhibitors like Rubraca and Lynparza continue to shape the treatment landscape of ovarian cancer.
Patients with glioblastoma multiforme (GBM) saw a 37 percent reduced risk of death and increased overall survival (OS) when treated with tumor treating fields (TTFields), according to a landmark analysis of the findings from the EF-14 trial.
Is it possible to actually get good at living with our disease?
A survivor shares her words of wisdom.
Opdivo (nivolumab) showed better long-term survival rates than expected for patients with metastatic non-small cell lung cancer (NSCLC).
In a recent study, people with certain disabilities were found to be less likely to follow recommended guidelines for colorectal cancer screening.
Formulating a plan and knowing how to react can help to ease emotions at a difficult time in life.
Playing the cancer card, if you haven't done it yet, more than likely you will soon.
Cancer survivor discusses interviewing for jobs and returning to employment after surviving breast cancer and melanoma.
Daily or weekly aspirin regimens may have a positive effect on colorectal cancer outcomes, a recent study found.
The amount of sleep a man gets can have an impact on prostate cancer outcomes, according to a recent study.
The results of phase 3 FLAURA trial could potentially change the treatment paradigm for some patients with lung cancer.
